Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma

•This predictive model was based on 239 patients with 41 months of mean follow up.•Assessed cancer specific, overall and metastasis free survival.•The c-index was 0.71 for OS, 0.72 for MFS and 0.74 for CSS.•Externally validated accuracy: 78.4%, 71.4%, and 75.3% for OS, CSS, and MFS, respectively. To...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2021-02, Vol.39 (2), p.133.e9-133.e16
Hauptverfasser: Abdul-Muhsin, Haidar, De Lucia, Noel, Singh, Vijay, Faraj, Kassem, Rose, Kyle, Cha, Stephen, Zhang, Nan, Judge, Nathanael, Navaratnam, Anojan, Tyson, Mark, Ho, Thai, Jacobsohn, Kenneth, Castle, Erik
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 133.e16
container_issue 2
container_start_page 133.e9
container_title Urologic oncology
container_volume 39
creator Abdul-Muhsin, Haidar
De Lucia, Noel
Singh, Vijay
Faraj, Kassem
Rose, Kyle
Cha, Stephen
Zhang, Nan
Judge, Nathanael
Navaratnam, Anojan
Tyson, Mark
Ho, Thai
Jacobsohn, Kenneth
Castle, Erik
description •This predictive model was based on 239 patients with 41 months of mean follow up.•Assessed cancer specific, overall and metastasis free survival.•The c-index was 0.71 for OS, 0.72 for MFS and 0.74 for CSS.•Externally validated accuracy: 78.4%, 71.4%, and 75.3% for OS, CSS, and MFS, respectively. To predict overall survival, cancer, and metastasis specific survival in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy (RNU). All nonmetastatic UTUC patients who underwent RNU with a curative intent at 1 institution between December 1998 and January 2017 were included.  Detailed data were collected. End points for this study included OS, CCS, and MFS. Univariate and multivariate analysis were conducted. Log Rank tests and Kaplan-Meier curves were generated. Backward elimination and boot strapping was used to identify the most parsimonious model with the smallest number of variables in order to predict the outcomes of interest. A separate second institution data base was used for external validation. There were 218 patients in the development cohort. Mean follow-up was 42 months (±39.6). There was 99 (45.4%) deaths, 28 (12.8%) cancer related deaths, 72 (33%) recurrences, and 54 (24.8%) metastases. The c-index for our model was 0.71 for OS, 0.72 for MFS and 0.74 for CSS. The nomograms did not show significant deviation from actual observations using our calibration plots. We divided the patient into 3 different groups (low, intermediate and high risk) based on their final total score for each outcome and compared them. On external validation our accuracy was 78.4%, 71.4%, and 75.3% for OS, CSS, and MFS survival respectively. We designed a predictive model for survival outcomes following RNU in UTUC. This model uses simple, readily available data for patients without the need for expensive or additional testing.
doi_str_mv 10.1016/j.urolonc.2020.08.021
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2452100117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143920303859</els_id><sourcerecordid>2452100117</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-44e026961af32c71f7831489d1e657bad60a033f6b3443560685347db2ba62243</originalsourceid><addsrcrecordid>eNqFkEtLxDAQgIMoPlZ_gtKjl9a8255ExBcseNGbENJ06mZpm5qkiv_eLLt69TTD8M3rQ-ic4IJgIq_Wxexd70ZTUExxgasCU7KHjklVspzyWu6nHJdVTjirj9BJCGuMCa8IOURHjGFZCyGO0dvzHI0bIJs8tNZE68asc33vvuz4nnmdarrPRphW3s0eIngw0Q3fCfLZPE3gs-i1iVm6Jq6gt4k22hs7ukGfooNO9wHOdnGBXu_vXm4f8-Xzw9PtzTI3TIqYcw6YyloS3TFqStKVFUuX1i0BKcpGtxJrzFgnG8Y5ExLLSjBetg1ttKSUswW63M6dvPuYIUQ12GCg7_UIbg6KckFJ-p6UCRVb1HgXgodOTd4O2n8rgtVGrFqrnVi1EatwpZLY1HexWzE3A7R_Xb8mE3C9BSA9-mnBq2AsjCZZ3ShTrbP_rPgBxtmNWw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452100117</pqid></control><display><type>article</type><title>Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Abdul-Muhsin, Haidar ; De Lucia, Noel ; Singh, Vijay ; Faraj, Kassem ; Rose, Kyle ; Cha, Stephen ; Zhang, Nan ; Judge, Nathanael ; Navaratnam, Anojan ; Tyson, Mark ; Ho, Thai ; Jacobsohn, Kenneth ; Castle, Erik</creator><creatorcontrib>Abdul-Muhsin, Haidar ; De Lucia, Noel ; Singh, Vijay ; Faraj, Kassem ; Rose, Kyle ; Cha, Stephen ; Zhang, Nan ; Judge, Nathanael ; Navaratnam, Anojan ; Tyson, Mark ; Ho, Thai ; Jacobsohn, Kenneth ; Castle, Erik</creatorcontrib><description>•This predictive model was based on 239 patients with 41 months of mean follow up.•Assessed cancer specific, overall and metastasis free survival.•The c-index was 0.71 for OS, 0.72 for MFS and 0.74 for CSS.•Externally validated accuracy: 78.4%, 71.4%, and 75.3% for OS, CSS, and MFS, respectively. To predict overall survival, cancer, and metastasis specific survival in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy (RNU). All nonmetastatic UTUC patients who underwent RNU with a curative intent at 1 institution between December 1998 and January 2017 were included.  Detailed data were collected. End points for this study included OS, CCS, and MFS. Univariate and multivariate analysis were conducted. Log Rank tests and Kaplan-Meier curves were generated. Backward elimination and boot strapping was used to identify the most parsimonious model with the smallest number of variables in order to predict the outcomes of interest. A separate second institution data base was used for external validation. There were 218 patients in the development cohort. Mean follow-up was 42 months (±39.6). There was 99 (45.4%) deaths, 28 (12.8%) cancer related deaths, 72 (33%) recurrences, and 54 (24.8%) metastases. The c-index for our model was 0.71 for OS, 0.72 for MFS and 0.74 for CSS. The nomograms did not show significant deviation from actual observations using our calibration plots. We divided the patient into 3 different groups (low, intermediate and high risk) based on their final total score for each outcome and compared them. On external validation our accuracy was 78.4%, 71.4%, and 75.3% for OS, CSS, and MFS survival respectively. We designed a predictive model for survival outcomes following RNU in UTUC. This model uses simple, readily available data for patients without the need for expensive or additional testing.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2020.08.021</identifier><identifier>PMID: 33069555</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Nomogram ; Survival ; Transitional cell carcinoma ; Upper tract urothelial carcinoma ; Urothelial carcinoma</subject><ispartof>Urologic oncology, 2021-02, Vol.39 (2), p.133.e9-133.e16</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-44e026961af32c71f7831489d1e657bad60a033f6b3443560685347db2ba62243</citedby><cites>FETCH-LOGICAL-c365t-44e026961af32c71f7831489d1e657bad60a033f6b3443560685347db2ba62243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urolonc.2020.08.021$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33069555$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdul-Muhsin, Haidar</creatorcontrib><creatorcontrib>De Lucia, Noel</creatorcontrib><creatorcontrib>Singh, Vijay</creatorcontrib><creatorcontrib>Faraj, Kassem</creatorcontrib><creatorcontrib>Rose, Kyle</creatorcontrib><creatorcontrib>Cha, Stephen</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Judge, Nathanael</creatorcontrib><creatorcontrib>Navaratnam, Anojan</creatorcontrib><creatorcontrib>Tyson, Mark</creatorcontrib><creatorcontrib>Ho, Thai</creatorcontrib><creatorcontrib>Jacobsohn, Kenneth</creatorcontrib><creatorcontrib>Castle, Erik</creatorcontrib><title>Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>•This predictive model was based on 239 patients with 41 months of mean follow up.•Assessed cancer specific, overall and metastasis free survival.•The c-index was 0.71 for OS, 0.72 for MFS and 0.74 for CSS.•Externally validated accuracy: 78.4%, 71.4%, and 75.3% for OS, CSS, and MFS, respectively. To predict overall survival, cancer, and metastasis specific survival in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy (RNU). All nonmetastatic UTUC patients who underwent RNU with a curative intent at 1 institution between December 1998 and January 2017 were included.  Detailed data were collected. End points for this study included OS, CCS, and MFS. Univariate and multivariate analysis were conducted. Log Rank tests and Kaplan-Meier curves were generated. Backward elimination and boot strapping was used to identify the most parsimonious model with the smallest number of variables in order to predict the outcomes of interest. A separate second institution data base was used for external validation. There were 218 patients in the development cohort. Mean follow-up was 42 months (±39.6). There was 99 (45.4%) deaths, 28 (12.8%) cancer related deaths, 72 (33%) recurrences, and 54 (24.8%) metastases. The c-index for our model was 0.71 for OS, 0.72 for MFS and 0.74 for CSS. The nomograms did not show significant deviation from actual observations using our calibration plots. We divided the patient into 3 different groups (low, intermediate and high risk) based on their final total score for each outcome and compared them. On external validation our accuracy was 78.4%, 71.4%, and 75.3% for OS, CSS, and MFS survival respectively. We designed a predictive model for survival outcomes following RNU in UTUC. This model uses simple, readily available data for patients without the need for expensive or additional testing.</description><subject>Nomogram</subject><subject>Survival</subject><subject>Transitional cell carcinoma</subject><subject>Upper tract urothelial carcinoma</subject><subject>Urothelial carcinoma</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkEtLxDAQgIMoPlZ_gtKjl9a8255ExBcseNGbENJ06mZpm5qkiv_eLLt69TTD8M3rQ-ic4IJgIq_Wxexd70ZTUExxgasCU7KHjklVspzyWu6nHJdVTjirj9BJCGuMCa8IOURHjGFZCyGO0dvzHI0bIJs8tNZE68asc33vvuz4nnmdarrPRphW3s0eIngw0Q3fCfLZPE3gs-i1iVm6Jq6gt4k22hs7ukGfooNO9wHOdnGBXu_vXm4f8-Xzw9PtzTI3TIqYcw6YyloS3TFqStKVFUuX1i0BKcpGtxJrzFgnG8Y5ExLLSjBetg1ttKSUswW63M6dvPuYIUQ12GCg7_UIbg6KckFJ-p6UCRVb1HgXgodOTd4O2n8rgtVGrFqrnVi1EatwpZLY1HexWzE3A7R_Xb8mE3C9BSA9-mnBq2AsjCZZ3ShTrbP_rPgBxtmNWw</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Abdul-Muhsin, Haidar</creator><creator>De Lucia, Noel</creator><creator>Singh, Vijay</creator><creator>Faraj, Kassem</creator><creator>Rose, Kyle</creator><creator>Cha, Stephen</creator><creator>Zhang, Nan</creator><creator>Judge, Nathanael</creator><creator>Navaratnam, Anojan</creator><creator>Tyson, Mark</creator><creator>Ho, Thai</creator><creator>Jacobsohn, Kenneth</creator><creator>Castle, Erik</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202102</creationdate><title>Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma</title><author>Abdul-Muhsin, Haidar ; De Lucia, Noel ; Singh, Vijay ; Faraj, Kassem ; Rose, Kyle ; Cha, Stephen ; Zhang, Nan ; Judge, Nathanael ; Navaratnam, Anojan ; Tyson, Mark ; Ho, Thai ; Jacobsohn, Kenneth ; Castle, Erik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-44e026961af32c71f7831489d1e657bad60a033f6b3443560685347db2ba62243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Nomogram</topic><topic>Survival</topic><topic>Transitional cell carcinoma</topic><topic>Upper tract urothelial carcinoma</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdul-Muhsin, Haidar</creatorcontrib><creatorcontrib>De Lucia, Noel</creatorcontrib><creatorcontrib>Singh, Vijay</creatorcontrib><creatorcontrib>Faraj, Kassem</creatorcontrib><creatorcontrib>Rose, Kyle</creatorcontrib><creatorcontrib>Cha, Stephen</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Judge, Nathanael</creatorcontrib><creatorcontrib>Navaratnam, Anojan</creatorcontrib><creatorcontrib>Tyson, Mark</creatorcontrib><creatorcontrib>Ho, Thai</creatorcontrib><creatorcontrib>Jacobsohn, Kenneth</creatorcontrib><creatorcontrib>Castle, Erik</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdul-Muhsin, Haidar</au><au>De Lucia, Noel</au><au>Singh, Vijay</au><au>Faraj, Kassem</au><au>Rose, Kyle</au><au>Cha, Stephen</au><au>Zhang, Nan</au><au>Judge, Nathanael</au><au>Navaratnam, Anojan</au><au>Tyson, Mark</au><au>Ho, Thai</au><au>Jacobsohn, Kenneth</au><au>Castle, Erik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2021-02</date><risdate>2021</risdate><volume>39</volume><issue>2</issue><spage>133.e9</spage><epage>133.e16</epage><pages>133.e9-133.e16</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>•This predictive model was based on 239 patients with 41 months of mean follow up.•Assessed cancer specific, overall and metastasis free survival.•The c-index was 0.71 for OS, 0.72 for MFS and 0.74 for CSS.•Externally validated accuracy: 78.4%, 71.4%, and 75.3% for OS, CSS, and MFS, respectively. To predict overall survival, cancer, and metastasis specific survival in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy (RNU). All nonmetastatic UTUC patients who underwent RNU with a curative intent at 1 institution between December 1998 and January 2017 were included.  Detailed data were collected. End points for this study included OS, CCS, and MFS. Univariate and multivariate analysis were conducted. Log Rank tests and Kaplan-Meier curves were generated. Backward elimination and boot strapping was used to identify the most parsimonious model with the smallest number of variables in order to predict the outcomes of interest. A separate second institution data base was used for external validation. There were 218 patients in the development cohort. Mean follow-up was 42 months (±39.6). There was 99 (45.4%) deaths, 28 (12.8%) cancer related deaths, 72 (33%) recurrences, and 54 (24.8%) metastases. The c-index for our model was 0.71 for OS, 0.72 for MFS and 0.74 for CSS. The nomograms did not show significant deviation from actual observations using our calibration plots. We divided the patient into 3 different groups (low, intermediate and high risk) based on their final total score for each outcome and compared them. On external validation our accuracy was 78.4%, 71.4%, and 75.3% for OS, CSS, and MFS survival respectively. We designed a predictive model for survival outcomes following RNU in UTUC. This model uses simple, readily available data for patients without the need for expensive or additional testing.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33069555</pmid><doi>10.1016/j.urolonc.2020.08.021</doi></addata></record>
fulltext fulltext
identifier ISSN: 1078-1439
ispartof Urologic oncology, 2021-02, Vol.39 (2), p.133.e9-133.e16
issn 1078-1439
1873-2496
language eng
recordid cdi_proquest_miscellaneous_2452100117
source Elsevier ScienceDirect Journals Complete
subjects Nomogram
Survival
Transitional cell carcinoma
Upper tract urothelial carcinoma
Urothelial carcinoma
title Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T10%3A31%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20prediction%20following%20radical%20nephroureterectomy%20for%20upper%20tract%20urothelial%20carcinoma&rft.jtitle=Urologic%20oncology&rft.au=Abdul-Muhsin,%20Haidar&rft.date=2021-02&rft.volume=39&rft.issue=2&rft.spage=133.e9&rft.epage=133.e16&rft.pages=133.e9-133.e16&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2020.08.021&rft_dat=%3Cproquest_cross%3E2452100117%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2452100117&rft_id=info:pmid/33069555&rft_els_id=S1078143920303859&rfr_iscdi=true